Xiamen Innovax Biotech

Xiamen Innovax Biotech Co., Ltd. (“Innovax”), with a registered captial of RMB 1.2 billion, was founded in Mar. 2005, It is the key vaccine arm of Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., and the only private-owned hightech enterprise engaged in vaccine reseach, development and production in Fujian Province.

Having been dedicated to the vaccine industry for nearly 20 years, Innovax and is committed to providing high-quality, affordable and innovative vaccines for human being. r, With a sustainable industry-academia-research model, Innovax closely collaborated with with the “National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD)” and established the world’s first E.coli platform for recombinant virus-like particle vaccines, and successfully launched the world’s first recombinant hepatitis E vaccine (Hecolin®) andthe first HPV vaccine (Cecolin®) in the Chinese market. (the 4th HPV vaccine in the world).